An update has been made to the recently released Influenza Immunization Policy (IIP) 2016-2017, originally referenced in the September 21 issue of The Link. You can view the updated version of the IIP here. An addition was made in Appendix A, under age group for which Fluad® was indicated.
The clarification supports the use of Fluzone® in adults 65 years of age or over, if Fluad® is not immediately available. Although Fluad® is the preferred product in individuals 65 years of age or older, it is more appropriate to use Fluzone® rather than sending the patient away without being immunized.
